Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies.
about
Rodent models of neuroinflammation for Alzheimer's diseaseMemoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's diseaseThe modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration.Epigenetic regulation of adult neural stem cells: implications for Alzheimer's disease.Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic miceTrigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structuresDissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegenerationNerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice.Intranasal "painless" human Nerve Growth Factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in App X PS1 miceSpatial navigation in complex and radial mazes in APP23 animals and neurotrophin signaling as a biological marker of early impairment.Nerve growth factor, neural stem cells and Alzheimer's disease.Cytoskeletal transport in the aging brain: focus on the cholinergic system.NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons.Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease.Tyrosine kinase nerve growth factor receptor switches from prosurvival to proapoptotic activity via Abeta-mediated phosphorylation.The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP.The role of the p75 neurotrophin receptor in cholinergic dysfunction in Alzheimer's disease.Does the term 'trophic' actually mean anti-amyloidogenic? The case of NGF.The chemokine CXCL12 mediates the anti-amyloidogenic action of painless human nerve growth factor.The depolarizing action of GABA controls early network activity in the developing hippocampus.Intranasal delivery of therapeutic proteins for neurological diseases.Nerve growth factor and Alzheimer's disease: new facts for an old hypothesis.Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer's disease.Intranasal therapeutic strategies for management of Alzheimer's disease.RNA processing-associated molecular mechanisms of neurodegenerative diseases.The Emerging Therapeutic Role of NGF in Alzheimer's Disease.Nicotine-induced enhancement of synaptic plasticity at CA3-CA1 synapses requires GABAergic interneurons in adult anti-NGF mice.Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mDissecting the role of sortilin receptor signaling in neurodegeneration induced by NGF deprivation.Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice.Regulation of Neurotrophic Factors During Pathogenic Tau-Aggregation: A Detailed Protocol for Double-Labeling mRNA by In Situ Hybridization and Protein Epitopes by Immunohistochemistry.Intravenous Transplantation of Human Umbilical Cord Blood Mononuclear Cells Overexpressing Nerve Growth Factor Improves Spatial Memory in APP/PS1 Transgenic Mice with a Model of Alzheimer’s Disease
P2860
Q26864804-26284CBE-5059-43A4-A5AE-ACFA817C07F6Q28820783-EE560A75-A3F3-4036-A05C-ACFFD630BF55Q33264215-6066D5F1-5599-470D-85FE-C1EC76713324Q33841944-2A852F13-8DD8-4D39-8E46-4BF905CDEC09Q33928463-B5D2E60F-00FF-4741-9BFE-4D14CC975F12Q33941603-9C64805C-046E-45A1-A053-163ABBEB2447Q33982246-CCBF3266-453D-4BAD-9DCD-2F0C0F577EF8Q34156343-AF447540-F5E1-4F1A-B1CA-9FDAB468D932Q34292513-DFFB2835-1FA2-45A8-A7DF-73F679B444F5Q34333481-F5BEA876-97C6-40B0-9CF1-B0E671B11F75Q36529555-0BEE22F3-81A3-4213-B521-56D14D36A1A6Q36729485-96F141B0-4707-4B3C-A8FB-AA86952D32FDQ36851804-7DC807BE-DBD9-4E05-9EDF-EC88B6725A0FQ36883772-5F403D74-E3FF-41DD-9A78-329249B64578Q37235009-33CFBAD2-4799-492F-9834-EDA07E0057ACQ37354744-88F98D8E-1953-4B0F-8722-7A8AA813FDEEQ37490683-730D13F0-CC76-44BD-8C94-1832AF4D2B5EQ37731918-292741F2-3F43-444C-AED7-D0A4B0722402Q37736982-D3D831F3-333F-4E69-950B-700721332000Q37806162-B3FBE672-D60F-4DF4-BFE5-9C358FA67652Q37880893-1D42D537-6D3A-430E-812D-0E1B2F96CE13Q38039856-92F719FD-9FAD-4B67-A18C-A9382AAEA0B6Q38062334-1B5ABCE2-DE17-48D7-BBA7-7636FE60A2FDQ38176935-E5283C39-07BE-42D9-8BED-2D2250C8E17FQ38658613-43CC5A55-7053-4D3D-9956-954CCE0AC93EQ38708387-BBC05334-FF99-4A38-A6A8-AAD6909840DEQ42498853-6B84A8D0-1E90-4512-AA3A-EE2DF284345EQ42737591-D3FF3D1F-3AC9-4697-8954-0B05F4DCE6F4Q43196635-F9234A3F-C7B7-4B4B-A4D0-BA620C1D1439Q44949726-B7C44FBE-E8D0-4265-909E-50FA3DFAEE2DQ48395249-AD01DBDB-53C0-4636-A8E0-91B05EB3A0E9Q58051585-6D86B1C5-608E-4A38-9FE3-493F6B561996
P2860
Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Beta-amyloid plaques in a mode ...... erve growth factor antibodies.
@en
Beta-amyloid plaques in a mode ...... erve growth factor antibodies.
@nl
type
label
Beta-amyloid plaques in a mode ...... erve growth factor antibodies.
@en
Beta-amyloid plaques in a mode ...... erve growth factor antibodies.
@nl
prefLabel
Beta-amyloid plaques in a mode ...... erve growth factor antibodies.
@en
Beta-amyloid plaques in a mode ...... erve growth factor antibodies.
@nl
P356
P1476
Beta-amyloid plaques in a mode ...... erve growth factor antibodies.
@en
P2093
Sabina Giannotta
P356
10.1006/MCNE.2002.1163
P577
2002-09-01T00:00:00Z